|
Goldman Sachs downgrades Glaxo to "sell"
BusinessWeek A Goldman Sacks analyst says GlaxoSmithKline's stock is overvalued as the British drugmaker prepares to face lower sales of its best-selling product, the asthma inhaler Advair. Goldman analyst Mark Beards notes the London-based drugmaker's shares have … Search Stocks To Watch Today Goldman Sachs downgrades Glaxo to "sell" |
View full post on asthma – Google News